Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 3/30/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Andrew Redd?

Andrew D. Redd

Staff Scientist

J. Hillis Miller Health Center

HQ Phone:  (352) 846-1309

Direct Phone: (206) ***-****direct phone

Email: a***@***.edu

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

J. Hillis Miller Health Center

1600 SW Archer Road Room M 452 MSB

Gainesville, Florida,32610

United States

Find other employees at this company (24,393)

Background Information

Affiliations

National Institutes of Health

Staff Scientist


Education

Ph.D.


Web References(13 Total References)


forums.poz.com

The study, published online in the Journal of Infectious Diseases, was led by Thomas C. Quinn, M.D., and Andrew D. Redd, Ph.D., of NIAID's Laboratory of Immunoregulation, and Maria J. Wawer, M.D., Ph.D., formerly of the Columbia University Mailman School of Public Health, New York City, and now with Johns Hopkins University Bloomberg School of Public Health, Baltimore.
"Previous studies of HIV superinfection have focused on individuals exposed to the virus through high-risk sexual activity or intravenous drug use," said lead author Dr. Redd. "Our findings suggest that HIV vaccine strategies designed to recreate the natural immune response to HIV may be insufficient to protect an individual from infection," Dr. Redd noted.


www.infectioncontroltoday.com

The research was led by Andrew D. Redd, PhD, staff scientist, and Thomas C. Quinn, MD, senior investigator, both in the Laboratory of Immunoregulation of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Redd and colleagues examined particular genetic sequences of HIV in blood samples collected between 1994 and 2002 from hundreds of HIV-infected heterosexuals participating in the Rakai Community Cohort Study in Rakai District, Uganda. According to Dr. Redd, this finding demonstrates that in the heterosexual transmission of HIV, the frequent natural selection of viral strains from early in the infection of the transmitting partner reduces viral diversity at the population level. Moreover, in four couples, the newly acquired strain was highly similar or identical to specific variants found in the transmitting partner at both the earliest time point and the time of transmission. The scientists hypothesize that these highly transmissible HIV strains from early infection were sustained in the blood at low levels or sequestered in certain cells for transmission at a later time. Related research by other scientists shows that HIV strains found in infected individuals during the early stages of infection have diversified little from the strain that caused infection. Thus, the fact that these early HIV strains somehow are maintained or persist at low levels for transmission later suggests they may have an evolutionary advantage at crossing the genital barrier and causing infection, compared with HIV strains that predominate later in infection, according to Redd.


www.positivelypositive.ca

The research was led by Andrew D. Redd, Ph.D., staff scientist, and Thomas C. Quinn, M.D., senior investigator, both in the Laboratory of Immunoregulation of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Dr. Redd and colleagues examined particular genetic sequences of HIV in blood samples collected between 1994 and 2002 from hundreds of HIV-infected heterosexuals participating in the Rakai Community Cohort Study in Rakai District, Uganda. According to Dr. Redd, this finding demonstrates that in the heterosexual transmission of HIV, the frequent natural selection of viral strains from early in the infection of the transmitting partner reduces viral diversity at the population level. Moreover, in four couples, the newly acquired strain was highly similar or identical to specific variants found in the transmitting partner at both the earliest time point and the time of transmission. The scientists hypothesize that these highly transmissible HIV strains from early infection were sustained in the blood at low levels or sequestered in certain cells for transmission at a later time. Related research by other scientists shows that HIV strains found in infected individuals during the early stages of infection have diversified little from the strain that caused infection. Thus, the fact that these early HIV strains somehow are maintained or persist at low levels for transmission later suggests they may have an evolutionary advantage at crossing the genital barrier and causing infection, compared with HIV strains that predominate later in infection, according to Dr. Redd. Anthony S. Fauci, M.D., NIAID director and chief of the NIAID Laboratory of Immunoregulation; and Andrew D. Redd, Ph.D., staff scientist in the NIAID Laboratory of Immunoregulation, are available for comment.


www.nccid.ca

The research was led by Andrew D. Redd, Ph.D., staff scientist, and Thomas C. Quinn, M.D., senior investigator, both in the Laboratory of Immunoregulation of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.


www.whatabouthiv.org

The study, published online in the Journal of Infectious Diseases, was led by Thomas C. Quinn, M.D., and Andrew D. Redd, Ph.D., of NIAID's Laboratory of Immunoregulation, and Maria J. Wawer, M.D., Ph.D., formerly of the Columbia University Mailman School of Public Health, New York City, and now with Johns Hopkins University Bloomberg School of Public Health, Baltimore.
"Previous studies of HIV superinfection have focused on individuals exposed to the virus through high-risk sexual activity or intravenous drug use," said lead author Dr. Redd. "Our findings suggest that HIV vaccine strategies designed to recreate the natural immune response to HIV may be insufficient to protect an individual from infection," Dr. Redd noted.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory